COSTEL BRINZAN, MARIANA ASCHIE, CATALIN NICOLAE GRASA, ANCA FLORENTINA MITROI, ELENA MATEI, GEORGETA CAMELIA COZARU THE MUTATION PROFILES OF KRAS AND BRAF GENES IN A ROMANIAN COLORECTAL CANCER COHORT Colorectal cancer (CRC) is one of most commonly diagnosed malignancies and management of CRC differs in according with patient’s characteristics, tumor type, differentiation, metastatic extension and KRAS/BRAF mutations. Based on this knowledge, we examined the relationship between KRAS/BRAF mutations in paraffin-embedded tumor specimens and some clinicopathological features at CRC in order to provide reliable results to the oncologists and so to contribute to the best care provided to the patients. A 56 of colorectal cancer samples were analyzed for the KRAS and BRAF mutational status using StripAssay method from ViennaLab, Austria. Assays for identification of KRAS/BRAF mutations were based on polymerase chain reaction (PCR) and reverse-hybridization. KRAS mutations were present in 50% (28 patients) of all analyzed CRC and were located in codons 12, 13 and 61. The most frequent types of mutations were substitution of glycine to valine in codon 12 (c.35G>T; 9/28), followed by glycine to aspartate on codon 13 (c.38G>A; 5/28). BRAF mutations were detected at 9 patients (16%) and in all cases Val600Glu mutation has been observed. In one case we reported a concomitant KRAS/BRAF mutation. According with current data, KRAS and BRAF mutations are associated with a poor patient prognosis in CRC, but KRAS mutation in codon 13 and BRAF appear to have a higher oncogenic potential.